DNA‐binding properties of novel cis‐ and trans platinum‐based anticancer agents in 2 human ovarian carcinoma cell lines
- 15 September 1995
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 62 (6), 717-723
- https://doi.org/10.1002/ijc.2910620612
Abstract
We have investigated the comparative initial DNA binding properties of 7 platinum-based anticancer drugs: 5 cis-oriented compounds, cisplatin, tetraplatin (Ormaplatin), JM118 [cis ammine dichloro (cyclohexylamine) platinum (II)], JM216 [bis-acetato cis ammine dichloro (cyclohexylamine) platinum (IV)] and JM149 [cis ammine dichloro (cyclohexylamine) trans dihydroxo platinum (IV)], and 2 trans-oriented compounds, transplatin and JM335 [trans ammine dichloro (cyclohexylamine) dihydroxo platinum (IV)] in SKOV-3 and CH1 human ovarian carcinoma cells. Unlike transplatin, the trans complex JM335 was comparably cytotoxic to its cis isomer JM149 and cisplatin. No significant correlation was observed between levels of total platinum bound to DNA after exposure to the 7 drugs and cytotoxicity in either cell line. Using a competitive enzyme-linked immunoabsorbent assay, DNA extracted from CM1 cells exposed to the 5 cis platinum drugs was recognized by the monoclonal antibody ICR4 (raised against DNA platinated by cisplatin) in the order JM118 > cisplatin > JM216 > tetraplatin > JM149; a strong positive correlation which just attained statistical significance was observed between recognition by ICR4 and cytotoxicity. In contrast, DNA extracted from CH1 cells exposed to the trans platinum drugs transplatin and JM335 was no more immunoreactive than control DNA. Using alkaline elution, interstrand cross-link levels after exposure to drug did not correlate with cytotoxicity in either cell line. The 5 cis drugs formed interstrand cross-links in both cell lines, whereas transplatin formed very low levels in SKOV-3 and undetectable levels in CH1. JM335 was efficient at forming interstrand cross-links in SKOV-3 but, notably, none were observed in CH1. In contrast, in the CH1 cells, single-strand breaks were observed with JM335 (but not with any other drug). The novel trans complex JM335 was unique, among the platinum drugs studied, in its ability to form both DNA interstrand cross-links and single strand breaks (DNA lesion formation being cell line dependent), a property which may account for its cytotoxicity.Keywords
This publication has 14 references indexed in Scilit:
- Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linkerBritish Journal of Cancer, 1994
- In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatinBritish Journal of Cancer, 1993
- A trans-platinum complex showing higher antitumor activity than the cis congenersJournal of Medicinal Chemistry, 1993
- Molecular Aspects of Platinum-DNA InteractionsPublished by Springer Nature ,1993
- Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexesBritish Journal of Cancer, 1992
- The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell linesBritish Journal of Cancer, 1991
- Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexesBritish Journal of Cancer, 1989
- DNA filter elution methods in anticancer drug developmentPublished by Springer Nature ,1987
- CisplatinAnnals of Internal Medicine, 1984
- X-ray induced DNA double strand break production and repair in mammalian cells as measured by neutral filter elutionNucleic Acids Research, 1979